Astrazeneca boosted as Covid-19 therapies offset vaccine drop
Although the UK pharmaceutical firm saw a drop in vaccine sales, other Covid-19 treatments have fared better, allowing Astrazeneca to raise its revenue guidance for 2022.
By Dong Lyu, bloomberg
Astrazeneca Plc raised its outlook for 2022 revenue as sales of its Covid-19 therapies offset a decline in its coronavirus vaccine.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Valneva plunges after Europe slashes Covid-19 vaccine order
For subscribers
